Mya Thomae, Harjit Kullar
Transgenomic has elected Mya Thomae to its board of directors. She is currently vice president of regulatory affairs at Illumina. Before that, she served as CEO of Myraqa, a diagnostics regulatory consulting firm, which was acquired by Illumina in 2014.
Transgenomic has also appointed Harjit Kullar vice president of marketing for biomarker discovery and genetic assays and platforms. He previously was content marketing leader for cross-functional global digital and web-based initiatives at Bio-Rad. Before that, he was director of product marketing, genomics, at Thermo Fisher Scientific.